Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is primed for long-term success with their expanding portfolio in the transplant rejection and oncology testing spaces, and recent financial growth and acquisitions suggest a positive outlook. However, potential risks include slow adoption of new products as CareDx enters the oncology market with their new test, AlloHeme. Their current revenue, expected to increase with recent acquisitions and divestitures, also indicates potential for long-term financial growth by 2027.

Bears say

CareDx is a healthcare company focused on precision medicine for transplant patients, known for its AlloMap and AlloSure tests. With a majority of its revenue coming from testing services, the company is expanding into new markets such as oncology with recent acquisitions. Upcoming earnings call and positive revisions to future revenue guidance, along with new acquisition and partnership opportunities, make it a promising stock in the long term. However, concerns about the impact of inorganic growth and potential dilution of shares could result in volatility and a potential decrease in stock value in the short term.

CareDx (CDNA) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 3 analysts, CareDx (CDNA) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.